MDA awards $1.4 million to speed SMA clinical trial by Repligen

December 16, 2010

Tucson, Ariz., Dec. 15, 2010 - The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

"Through its translational research program MDA makes strategic investments that encourage biopharmaceutical companies to give priority to drug development efforts focused on therapeutic approaches for neuromuscular diseases," said Valerie Cwik, M.D., MDA Executive Vice President - Research and Medical Director. "Here, a new compound with therapeutic potential for SMA has been identified, and the MDA grant will cover costs associated with pre-clinical testing, as well as early phase human clinical trials in healthy volunteers and patients which are planned for 2011."

The new MDA research funds will enable Repligen to move its lead compound for SMA, RG3039, into human clinical trials after completing final preclinical steps required by the U.S. Food and Drug Administration. RG3039 is an inhibitor of an RNA processing enzyme that, in two mouse models for SMA pioneered by MDA-funded investigators, significantly increases production of SMN, a protein that's deficient in patients with SMA. The initial discovery and development of RG3039 was conducted by Families of SMA and was licensed by Repligen in 2009.

"RG3039 could change the course of the disease," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors. "In pre-clinical models for SMA, RG3039 has increased production of the vital SMN protein, improving both mobility and lifespan."

"Since studies show a correlation between the amount of SMN protein present and the severity of disease," Howell added, "some 20,000 Americans living with SMA have every reason to be keenly interested in the planned human clinical trial of RG3039."

SMA is a genetic neuromuscular disease that involves the loss of nerve cells (motor neurons) in the spinal cord. Symptoms typically occur in infancy, but the disease can often show up in early or late childhood and rarely in adulthood. It causes progressive muscle weakness in the body, including muscles needed for breathing. There are several different types of SMA. The most severe form, SMA type 1 or "infantile SMA," is present in newborns and is often fatal before the age of two.

SMA is caused by a defect in the SMN1 (for "survival of motor neurons) gene, which causes abnormally low levels of the protein SMN. A second gene, called SMN2, is almost identical to SMN1; but the genetic instructions in the SMN2 gene are altered, resulting in production of only small amounts of the full length protein. However, scientists have discovered that patients with more copies of the SMN2 gene generally have less severe forms of SMA, because they presumably make more full-length SMN.

Repligen plans to conduct two phase I trials to test the drug's safety. The first trial will be conducted in healthy volunteers after Repligen receives FDA approval. The second study will involve people with SMA.

In tandem with the phase I human trials, researchers also plan to conduct studies in mouse models to better predict optimal doses for patients, as well as identify a biomarker, or benchmark, that can be used to better quantify the effects of RG3039 in patients. For more information visit: http://quest.mda.org/news/14-million-mda-grant-will-help-develop-sma-drug.

Previously, MDA has granted $1.73 million to Repligen to develop drug treatment therapies for Friedreich's Ataxia, a genetic neurodegenerative disease that affects coordination and balance, skeletal muscles and the heart.

About MDA

The Muscular Dystrophy Association is the nonprofit health agency dedicated to curing muscular dystrophy, SMA and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education. Long the leading non-governmental funding source for neuromuscular disease research, MDA is the first nonprofit to earn a Lifetime Achievement Award from the American Medical Association ("for significant and lasting contributions to the health and welfare of humanity"). The latest $1.4 million MDA grant to Repligen is part of $16 million in new multi-year research funding approved by the MDA Board of Directors during its Dec. 10 meeting in New York.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology. We have a core competency in the development and manufacturing of biologics products, which is the basis for our bioprocessing business and we have out-licensed certain biologics intellectual property, which provide ongoing sources of revenue. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at www.repligen.com.

Muscular Dystrophy Association

Related Protein Articles from Brightsurf:

The protein dress of a neuron
New method marks proteins and reveals the receptors in which neurons are dressed

Memory protein
When UC Santa Barbara materials scientist Omar Saleh and graduate student Ian Morgan sought to understand the mechanical behaviors of disordered proteins in the lab, they expected that after being stretched, one particular model protein would snap back instantaneously, like a rubber band.

Diets high in protein, particularly plant protein, linked to lower risk of death
Diets high in protein, particularly plant protein, are associated with a lower risk of death from any cause, finds an analysis of the latest evidence published by The BMJ today.

A new understanding of protein movement
A team of UD engineers has uncovered the role of surface diffusion in protein transport, which could aid biopharmaceutical processing.

A new biotinylation enzyme for analyzing protein-protein interactions
Proteins play roles by interacting with various other proteins. Therefore, interaction analysis is an indispensable technique for studying the function of proteins.

Substituting the next-best protein
Children born with Duchenne muscular dystrophy have a mutation in the X-chromosome gene that would normally code for dystrophin, a protein that provides structural integrity to skeletal muscles.

A direct protein-to-protein binding couples cell survival to cell proliferation
The regulators of apoptosis watch over cell replication and the decision to enter the cell cycle.

A protein that controls inflammation
A study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.

Resurrecting ancient protein partners reveals origin of protein regulation
After reconstructing the ancient forms of two cellular proteins, scientists discovered the earliest known instance of a complex form of protein regulation.

Sensing protein wellbeing
The folding state of the proteins in live cells often reflect the cell's general health.

Read More: Protein News and Protein Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.